SMSandra Margielewska-Davies

Sandra Margielewska-Davies

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Margielewska-Davies has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer

    by Sandra Margielewska-Davies, Wayne Croft, Hayden Pearce, Natalie To, Fouzia Zayou, Falguni Meghrajani, Jing Zhang, Claudia M. A. Pinna, Laura Bills, Andrew D. Beggs, et al.

    The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing but clinical outcomes remain poor and new treatments are required. IGF2BP3 is an oncofetal m6A-reading RNA regulatory protein whose expression is commonly observed in PDAC and which may represent an important therapeutic target. IGF2BP3 protein is expressed in >95% of primary tumours whilst RNA expression ranges from 3 to 3000-fold above normal epithelium. siRNA knockdown reveals IGF2BP3 to strongly support expression of gene programs related to DNA replication, cell cycle and apoptosis, TNF signalling and epithelial-mesenchymal transition. Direct sequencing of native RNA further reveals IGF2BP3-mediated enhancement of 863 RNA isoforms with suppression of 389 isoforms. m6A, m5C and pseudouridine (ψ) RNA modifications were seen in 97% of transcripts within the PDAC transcriptome and enriched within MYC gene targets. IGF2BP3 regulated the pattern of RNA modification with a substantial impact on m5C modifications of miRNA and scRNA, and genes associated with regulation of TNF signalling. Knockdown of IGF2BP3 expression in primary tumour organoid cultures suppressed proliferation and elicited apoptosis, indicating a critical requirement for IGF2BP3 within malignant stem cells. These data show that IGF2BP3 is expressed consistently in PDAC, plays a dominant role in regulation of RNA splicing and modification, and supports cancer stem cell proliferation and survival. IGF2BP3 therefore occupies a critical position within the RNA regulon of PDAC and represents an important therapeutic target in this tumour of unmet need.

  • Open Access

    Supplementary Fig. S1 - S12 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    Supplementary Figures S1 - S12

  • Open Access

    Figure 1 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    High-level cell type atlas of the PDAC tumor microenvironment. A, UMAP embedding of scRNA-seq data from 3 PDAC patient samples overlaid with high level cell type annotation (i). UMAP embedding overlaid with sample identification, and proportions of T, B, and NK cells identified in each sample (ii). UMAP embedding highlighting high level T-cell subsets (iii). Dotplot of the top markers expressed in each high-level cell type (iv). B, Representative plots showing T, B, and NK cell identification in matched PBMC and TIL from patients with PDAC by flow cytometry (i). Graphs showing proportions of T, B, and NK cells in PBMC and TIL (n = 15). Each bar in the waterfall plot represents a patient in (ii), and each dot represents a patient in (iii). C, Representative plots showing gating used to identify T-cell subsets in PBMC and TIL from patients with PDAC by flow cytometry (i). Quantification of αβ and γδ T cells (ii), and NK T and MAIT cells (iii) in PBMC and TIL (n = 15). Comparison of the CD4/CD8 T cell ratio between PBMC and TIL (n = 10) (iv). Horizontal lines represent median, boxes represent quartiles and whiskers represent min and max values. Data analyzed using Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.

  • Open Access

    Figure 2 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    Characterization of CD4+ T-cell populations within the PDAC tumor microenvironment. A, Dot plot of the top markers expressed in each CD4+ T-cell cluster identified via Louvain clustering of scRNA-seq data from CD4+ T cells from 3 PDAC tumor tissue samples (i). Where identifiable in the data, clusters are annotated with known CD4+ T-cell phenotypes. UMAP embedding of CD4+ T cells overlaid with Louvain cluster labels (ii). B, A 35-parameter CyTOF analysis of CD45+ cells from PDAC patient PBMC and TIL (n = 10). t-SNE plots shows PhenoGraph-clustered CD4+ T-cell populations in PBMC and TIL. C, Stacked bar graph showing the proportion of Naïve, EM, CM, and TEMRA subsets in CD4+ T cells generated from the data in (B). D, Bar graph comparing the proportion of each annotated CD4+ EM subset (TEM1-5) in PBMC vs. TIL, generated using the data in (B). E, Differential expression analysis distinguishing CD4+ Th17 from other non-Treg CD4+ T-cells in scRNA-seq data, first presented in Fig. 1. Selected genes are labelled, and colored points indicate genes that are differentially expressed [BH adjusted P < 0.01 and absolute (average logFC) > 0.5]. F, Quantification of CD4+ Th17 based on dual expression of CCR6 and CD161, performed using the data in (B). Representative contour plots comparing Th17 in PBMC and TIL (i). Box and whisker plot comparing the proportion of Th17 among total memory (CD45RA–) non-Treg CD4+ T cells in PBMC and TIL (ii). G, Quantification of CD4+ Treg cells based on expression of CD25 and CD127, generated using the data in (B). Representative contour plot of Treg cells (CD25+CD127low) from PDAC TIL (i). Box and whisker plot comparing the proportion of Th17 cells in PBMC and TIL (ii). H, Histograms comparing expression levels of activation and differentiation markers on total Tregs from PBMC and TIL, generated using the data in (B). Horizontal lines represent median, boxes represent quartiles and whiskers represent minimum and maximum values. Data analyzed using Wilcoxon matched-pairs signed rank test. CyTOF comparisons analyzed using Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01.

  • Open Access

    Figure 4 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    Checkpoint inhibitory receptor expression on PDAC T cells. A, Expression of checkpoint inhibitory receptors PD-1, TIGIT, Tim-3, LAG-3, and CTLA-4 on CD4+ and CD8+ T cells from matched PBMC and TIL was examined by flow cytometry (n = 14). Representative flow cytometric zebra plots show expression of each checkpoint inhibitory receptor alongside PD-1 expression for CD4+ and CD8+ T cells from PBMC and TIL. B, Scatter plots compare the proportion of each checkpoint receptor (i) and dual PD-1 and TIGIT expression (ii) on CD4+ and CD8+ T cells from PBMC and TIL. C, Venn diagrams show the overlapping expression of checkpoint inhibitory receptors on CD4+ and CD8+ T cells from PBMC and TIL. D, t-SNE plot of PDAC TIL CyTOF data first presented in Fig. 2B showing the expression level of TIGIT and PD-1. CD8+ TRM cells are highlighted. E, Box and whisker plot, generated using the CyTOF data first presented in Fig. 2B, compares dual TIGIT and PD-1 expression on TRM and non-TRM CD8+ T cells from PDAC TIL. F, Box and whisker plots, generated using the CyTOF data first presented in Fig. 2B, compare the MMI of PD-1 and TIGIT on TRM and non-TRM CD8+ T cells from PDAC TIL. G, Multiplex IHC staining shows T-cell staining around CD20+ B cells in lymphoid structures (scale bar: 100 μm; i); expression of PD-1 and TIGIT across the follicle with TIGIT focused within the T-cell zone (scale bar: 50 μm) and PD-1+TIGIT+ coexpression on CD8+ T cells (scale bar: 10 μm; ii). Horizontal lines represent median, boxes represent quartiles and whiskers represent minimum and maximum values. Data analyzed using Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Open Access

    Figure 5 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    Expression of PD-1 and TIGIT ligands in the PDAC TME. A, Average expression profiles of TIGIT and PD-1 family receptors/ligands on all annotated cell subsets from scRNA-seq data first presented in Fig. 1. B, Representative confocal images of immunofluorescent staining for PD-1 and TIGIT ligands on tumor epithelium (EpCAM+), macrophages (CD68+), and stroma/fibroblasts (α-SMA+) using PDAC FFPE tissue (n = 10 patients). White arrows indicate examples of dual staining. Scale bars: 50 μm. C, Multiplex IHC staining of PD-1 and TIGIT ligands within ectopic lymphoid structures (scale bar: 100 μm; i). Digital representation of cell segmentation and localization of PD-L1+CD155+ cells and PD-1+TIGIT+ CD8+ T cells (ii). Direct engagement of a PD-1+TIGIT+ CD8+ T cell with a PD-L2+CD155+ cell within the T-cell area (scale bar: 10 μm; iii). Dashed line represents the border between the T- and B-cell areas. D, A 35-parameter CyTOF panel was used to determine the expression of PD-1 and/or TIGIT ligands on different myeloid-cell subsets in matched PBMC and TIL samples from patients with PDAC (n = 10). t-SNE plot shows PhenoGraph clusters of myeloid-enriched cell populations from combined PBMC and TIL (i), and cells stratified by sample type (ii). E, Heat map shows median expression level of key markers in each PhenoGraph cluster. F, t-SNE plots show the expression level of PD-1 and TIGIT ligands.

  • Open Access

    Figure 6 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    The effect of T-cell proliferation and cytokine secretion following anti–PD-1 and anti-TIGIT blockade. A, Schematic representation of the CHO-aAPC:T-cell coculture assay. T cells from patients with PDAC were cocultured with aAPCs expressing PD-1 and/or TIGIT ligands for 4 days in the presence of anti-TIGIT and/or anti–PD-1, or with a mAb isotype control. B, Cell culture supernatants from 6 patients in triplicate wells were harvested after 4 days of coculture and IFNγ was quantified by ELISA. Box and whisker graphs compare the levels of IFNγ secreted under 3 conditions—without ligand expression, with ligand expression, and for both ligand expression and mAb blockade with either CD155, CD112, or PD-L1 (i) or dual CD155 and PD-L1 (ii) expression. C, Proliferation of T cells (n = 9 patients) following coculture was determined by CTV dilution and analyzed by flow cytometry on day 4. Box and whisker graphs compare fold change in T-cell proliferation following single or dual CD155/PD-L1 mAb blockade compared with without (isotype mAb) blockade with CHO-aAPCs expressing both CD155 and PD-L1. Horizontal lines represent median, boxes represent quartiles and whiskers represent minimum and maximum values. Data analyzed using Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01.

  • Open Access

    Supplementary Tables S1 - S5 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

  • Open Access

    Figure 3 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade

    by Hayden Pearce, Wayne Croft, Samantha M. Nicol, Sandra Margielewska-Davies, Richard Powell, Richard Cornall, Simon J. Davis, Francesca Marcon, Matthew R. Pugh, Éanna Fennell, et al.

    Characterization of CD8+ T-cell populations within the PDAC tumor microenvironment. A, Dot plot of the top markers expressed in each CD8+ T-cell cluster identified via Louvain clustering of scRNA-seq data (first presented in Fig. 1) from CD8+ T cells (i). UMAP embedding of CD8+ T cells from the 3 PDAC patient samples overlaid with Louvain cluster label (ii). B, CyTOF analysis of CD45+ cells from PDAC patient PBMC and TIL (n = 10), using data first used in Fig. 2B. t-SNE plots show PhenoGraph-clustered CD8+ T-cell populations in PBMC and TIL. C, Representative contour plot showing CD8+ TRM cells in PDAC TIL based on positive expression of CD69 and CD103, generated using the data in Fig. 2B (i). Box and whisker plot showing the proportion of CD8+ TRM cells in PBMC and TIL, generated using the data in Fig. 2B (ii). D, UMAP embedding, performed using scRNA-seq first presented in Fig. 1, overlaid with module score quintiles and module score distributions by CD8 T-cell cluster from scoring a core module of genes overexpressed in TRM T-cells (i). Differential expression analysis distinguishing TRM-like cells (clusters CD8_1 and CD8_6) from non-TRM cells (ii). Selected genes are labelled, and colored points indicate genes that are differentially expressed [BH adjusted P < 0.01 and absolute (average logFC) > 0.5]. E, Comparison of memory T-cell markers in CD8+ TRM and non-TRM in PDAC TIL, performed using the data in Fig. 2B. Bar graph comparing the proportion of Naïve, EM, CM, and TEMRA subsets in CD8+ TRM and non-TRM cells (i). Bar graph comparing the CD27 and CD28 expression pattern in CD8+ EM T-cells within TRM and non-TRM cells (ii). F, Line graphs comparing T-cell activation and differentiation marker expression on CD8+ TRM versus non-TRM cells in PDAC TIL, generated using the data in Fig. 2B. G, Representative contour plots (i) and quantification (ii) of CD39+ CD8+ TRM cells in PBMC and TIL, generated using the data in Fig. 2B. H, DFS analysis of patients with PDAC from the TCGA-PAAD dataset based on the expression level of ITGAE (CD103) in tumor tissue. Horizontal lines represent median, boxes represent quartiles and whiskers represent min and max values. Data analyzed using Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01.

  • Open Access

    CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD

    by Kriti Verma, Wayne Croft, Sandra Margielewska-Davies, Hayden Pearce, Christine Stephens, Diana Diaconescu, Sarah Bevington, Charles Craddock, Rasoul Amel-Kashipaz, Jianmin Zuo, et al.

    Graft-versus-host disease (GVHD) remains a major challenge after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and further understanding of its immunopathology is crucial for developing new treatments. CD70 interacts with CD27 and is upregulated transiently on T cells after recent T-cell receptor (TCR) engagement. Here, we investigated the functional and clinical significance of CD70 expression on T cells during the early posttransplantation period. CD70 was expressed on a subset of highly activated memory T cells within the first 2 weeks after transplant, which then gradually declined in most patients. CD70+ T cells exhibited an open chromatin landscape and a transcriptional profile indicative of intense Myelocytomatosis oncogene (MYC)-driven glycolysis and proliferation. CD4+ and CD8+CD70+ T-cell numbers increased by ninefold and fourfold, respectively, during acute GVHD (aGVHD) and displayed an oligoclonal TCR repertoire. These cells expressed CCR4 and CCR6 chemokine receptors and were markedly increased in aGVHD tissue samples. Furthermore, CD70+ T cells demonstrated alloreactive specificity in vitro, and proliferative and inflammatory cytokine responses were markedly attenuated by CD70 blockade. These findings identify CD70 as a marker of highly activated alloreactive T cells and reveal the potential therapeutic importance of inhibiting CD27-CD70 costimulation in both the prophylaxis and treatment of aGVHD.